A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Key facts

Sponsor

Eli Lilly and Company

Principal Investigator

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)

Eli Lilly and Company

Intervention

LY4066434.(drug)

Enrollment

750 enrolled

Eligibility

18 years · All sexes

Timeline

2024 – 2030

Study locations (30)

• University of Alabama at Birmingham, Birmingham, Alabama, United States
• Mayo Clinic, Phoenix, Arizona, United States
• City of Hope, Duarte, California, United States
• University of California, Los Angeles (UCLA), Los Angeles, California, United States
• University of Colorado Denver, Denver, Colorado, United States
• Yale University School of Medicine - Yale Cancer Center, New Haven, Connecticut, United States
• The University of Chicago Medical Center (UCMC), Chicago, Illinois, United States
• Indiana University (IU), Indianapolis, Indiana, United States
• Massachusetts General Hospital, Boston, Massachusetts, United States
• Dana-Farber Cancer Institute, Boston, Massachusetts, United States
• Henry Ford Health System, Detriot, Michigan, United States
• South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids, Michigan, United States
• Mayo Clinic - Rochester, Rochester, Minnesota, United States
• Columbia University, New York, New York, United States
• David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York, New York, United States
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Small cell lung cancer

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1, PHASE2NCT06694454
  Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
  National Cancer Institute (NCI)
• RECRUITINGNANCT07398599
  Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study
  Second Affiliated Hospital of Nanchang University
• RECRUITINGPHASE1, PHASE2NCT07480213
  Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
  Beijing Biotech
• RECRUITINGPHASE1, PHASE2NCT07227597
  A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
  Merck Sharp & Dohme LLC
• RECRUITINGPHASE1NCT07348211
  First in Human Study of SIM0610 in Solid Tumors
  Jiangsu Simcere Pharmaceutical Co., Ltd.
• RECRUITINGNANCT07161310
  Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint Inhibitors
  Goethe University
• RECRUITINGPHASE2NCT07304739
  Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases
  Tianjin Medical University Cancer Institute and Hospital
• RECRUITINGPHASE3NCT07185997
  Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
  ArriVent BioPharma, Inc.

See all trials for Small cell lung cancer →